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Cost effectiveness and affordability 
of trastuzumab in sub-Saharan Africa for early 
stage HER2-positive breast cancer
Noga Gershon1* , Yakir Berchenko1, Peter S. Hall2 and Daniel A. Goldstein3,4
Abstract 
Background: Breast cancer is the second most common cancer worldwide, the most common among women, and 
the most frequent cause of death among women in less developed regions. Trastuzumab is a humanized monoclonal 
antibody that downregulates the extracellular domain of the HER2 protein. Using trastuzumab to treat women with 
localized HER2-positive breast cancer has been shown to improve survival. The objective of this study is to explore the 
cost-effectiveness of adjuvant trastuzumab, from a societal perspective, in 11 African countries. In addition, we aimed 
to establish value-based prices for trastuzumab based on the gross domestic product per capita in each country.
Methods: We developed a Markov model in order to assess the costs and benefits associated with trastuzumab 
treatment over a lifetime horizon. A probabilistic sensitivity analysis was performed in order to estimate the impact of 
uncertainty of parameter-values on the results. Efficacy inputs were derived using clinical trial data from non-African 
countries.
Results: In the base case analysis, trastuzumab yielded a gain ranging from 0.92 LYs in Nigeria to 1.07 LYs in South 
Africa, and 0.9 QALYs in Nigeria to 1.02 QALYs in South Africa. The incremental cost ranged from 19,561 USD in Nigeria 
to 19,997 USD in Congo, and an incremental cost-effectiveness ratio ranging from 19,534 USD/QALY in South Africa 
to 21,697 USD/QALY in Nigeria. Using willingness to pay estimates based on World Health Organization recommenda-
tions, trastuzumab appear to not be cost-effective in all countries analyzed. Cost-effectiveness estimates were most 
sensitive to the discount rate, trastuzumab cost, and the hazard ratio.
Conclusions: Trastuzumab does not appear to be cost effective in the African countries analyzed. In order for trastu-
zumab to be cost-effective, the costs of treatment would require significant discounts.
Keywords: Cost-effectiveness, Trastuzumab, Sub-Saharan Africa
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Background
Non-communicable diseases, are responsible for about 
70% of deaths worldwide. It was predicted that by 2050, 
24 million people will be diagnosed with cancer annually. 
Among them, up to 70% will be from low-income and 
middle-income (LMICs) countries [1]. The increasing 
incidence in these countries is due to lifestyle changes, 
increased life expectancy, and the improvements in 
treating infectious diseases [1]. Health care systems in 
many African countries are struggling to deal with the 
increasing demand caused by the increasing number of 
cancer patients. Furthermore, using the same care guide-
lines from high-income countries in a region with less 
resources and fewer personnel is inappropriate. The high 
mortality of cancer patients in Africa is multifactorial—
due to poor infrastructure, lack of skilled health-care 
workers, advanced stage at diagnosis, reliance on tradi-
tional therapy, few treatment options, and poor compli-
ance [2]. According to a report published by the Institute 
of Medicine (IOM), the burden of cancer is growing in 
many poor countries [3]. Breast cancer is the second 
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most common cancer worldwide, and the most common 
among women. Moreover, breast cancer is the fifth most 
common cause of death overall, the most frequent cause 
of death among women in less developed regions, and 
the second cause of death in more developed regions [4].
Trastuzumab is a humanized monoclonal antibody that 
downregulates the extracellular domain of the HER2 pro-
tein. Trastuzumab significantly increases the cure rate in 
patients with HER2 positive localized breast cancer, and 
has therefore become a standard adjuvant treatment for 
early stage breast cancer in many countries [5]. In a sur-
vey conducted on breast cancer management in Africa, 
trastuzumab was available in 10 out of 19 facilities. How-
ever, only 5% of the patients were able to afford it [6]. Due 
to minimal availability of data, there is very scant evi-
dence regarding actual treatment patterns in sub-Saha-
ran Africa. Furthermore, it was found that many breast 
cancer patients in sub-Saharan Africa are usually treated 
with tamoxifen regardless of their receptor status [2].
The aim of this study was to explore the cost-effective-
ness and affordability of adjuvant trastuzumab treatment 
for HER2-positive breast cancer in 11 countries in sub-
Saharan Africa, from a societal perspective. The decision 
whether an intervention is good value for money or not 
is determined by comparing the incremental cost-effec-
tiveness ratio result (ICER) in each country to a specific 
willingness to pay (WTP) threshold [7]. In LMICs, the 
threshold suggested by the World Health Organization 
(WHO) is related to the annual gross domestic prod-
uct (GDP) per capita of each country. If the ICER of the 
intervention is less than 1xGDP per capita, the inter-
vention is considered as very cost-effective. If the ICER 
is between 1 and 3× GDP per capita, the intervention 
is considered cost-effective. Otherwise, it is consid-
ered not cost-effective [7]. In order to use WHO’s sug-
gested threshold, the ICER should be in terms of cost 
per DALY (disability-adjusted life year) [7], however 
according to a study that reviewed the cost-effectiveness 
literature, it was found that cost-per quality adjusted 
life year (QALY) is used to address diseases in wealthier 
countries such as cancer, whereas cost-per DALY tend 
to address more prevalent diseases in low income coun-
tries such as HIV. Furthermore, QALYs tend to be used 
for interventions that evaluate pharmaceuticals, while 
DALYs are used to evaluate interventions that are more 
focused on immunizations [8]. Additionally, the use of a 
figure close to the GDP per capita as a cost-effectiveness 
threshold is widespread in many countries. For exam-
ple, the United States cost-effectiveness ratio, as for 2016 
was 50,000 USD per QALY, while their GDP per capita 
was 57,588 USD. The United Kingdom cost-effectiveness 
threshold as for 2016, was set to be 20,000–30,000 GBP/
QALY (~ 25,245–37,867 USD per QALY), and the GDP 
per capita was 40,412 USD [9]. The Netherlands cost-
effectiveness threshold was set to 40,000 EUR per QALY 
(~ 45,498 USD), and the GDP per capita was 45,637 USD 
[10]. Australia’s GDP per capita is 53,800 USD, however 
they do not have a specific threshold for funding a new 
medicine. However, it is more likely that a new drug that 
costs less than 50,000 USD per QALY will recommended 
for funding [11]. In Mexico, when deciding whether or 
not to include a certain technology in the public health-
care system, the GDP per capita is defined to be the cost-
effectiveness threshold [12]. This threshold is also being 
used in Chile [13] and Colombia [14] to define a technol-
ogy as cost-effective. Following that, we decided to use 
the GDP per capita threshold to determine whether tras-
tuzumab is cost-effective or not in sub-Saharan Africa. 
Furthermore, with DALY being typically an interme-
diate between LY and QALY, since in our paper the LY 
and QALY obtained are not far apart (and thus, replacing 
either by DALY will not change much), the extra page-
space and demand from the reader seem unwarranted. 
An additional objective of this paper was to estimate a 
value-based price (VBP) for each country based on each 
country’s GDP per capita.
Methods
We developed a Markov model with monthly cycles and 
life time horizon using the Rstudio platform. The model 
was used to estimate the costs and health outcomes (LYs, 
QALYs) associated with two treatment strategies (chemo-
therapy with and without trastuzumab) for treating early 
stage HER2 positive breast cancer. The chemotherapy 
regimen used in this model is anthracycline based chem-
otherapy as depicted in the HERA trial [15, 16]. However, 
there are multiple different approaches regarding tim-
ing and precise therapy such as the use of taxane based 
therapy, depending on the patient and stage of disease. 
However, as the precise treatment patterns in sub-Saha-
ran Africa are unknown, it would only be speculation to 
suggest that one chemotherapy is used in preference of 
another. This limits the applicability of this model.
Model structure
The Markov model was developed using the model 
structure and data used in a recently published study 
concerning the cost-effectiveness of trastuzumab in 
South-America [17]. The structure of the model was 
quite similar to several previously published cost-effec-
tiveness analyses concerning trastuzumab [18–21]. The 
HERA trial is considered by many to be the most piv-
otal trial due to the statistically significant results. There 
have however been considerations that a shorter duration 
of treatment may be a reasonable option. The FinnHER 
study evaluated the use of trastuzumab for only 9 weeks 
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compared to no trastuzumab [22]. However this short 
duration was not compared to the longer duration and 
did not become accepted as a standard of care around the 
world. One exception to this was in New Zealand, where 
the government initially provided 9 weeks of therapy, but 
then decided to provide 12  months of therapy [23] fol-
lowing demonstration of lack of non-inferiority with the 
shorter course [24].
Other studies such as the PERSEPHONE trial [25] have 
assessed the efficacy of using 6  months of trastuzumab, 
however this has still not become the standard of care 
due to multiple statistical considerations. A recent meta-
analysis suggested preferential clinical outcomes with 
12 months of therapy.
The inputs of the model were based upon the HERA 
trial [15, 16, 26] which was used to construct prior cost-
effectiveness analyses. Even though the HERA trial was 
conducted in HIC, we had no reason to believe that the 
efficacy and side effect profile are different among differ-
ent ethnic groups. The model illustrated in Fig. 1, consists 
of five different states: “Remission” (R), “Loco-regional 
recurrence” (LR), “Distant recurrence” (DR) including 
metastasis, “Breast cancer death” (BCD), and “Death 
due to other causes” (D). Patients enter the model from 
the “Remission” state, they can move to “Loco-regional 
recurrence” (LR) and return to “Remission” after a suc-
cessful treatment. They can move from the “Remission” 
(R) state to “Distant recurrence” (DR) when metastasis is 
developed. Patients in “Loco-regional recurrence” (LR) 
state can move to “Distant recurrence” (DR). Patients in 
all states can move to the “Death due to other causes” (D) 
state due to all-cause mortality. Only patients in “Distant 
recurrence” (DR) state can move to “Breast cancer death” 
(BCD). The influence of trastuzumab on the patients was 
modeled by changing the transition probabilities from R 
to DR and from LR to DR for the trastuzumab arm, using 
the hazard ratio. The probability of moving from DR to 
BCD is identical for both arms. This is because using 
trastuzumab only delays or prevents a patient from mov-
ing to the DR state. Once a patient has arrived in the DR 
state, the probability of staying in this state, or moving to 
other states is identical regardless of the patient’s arm. It 
was assumed that the effect of trastuzumab lasted 5 years 
and that there were no cancer recurrences after 20 years 
of follow-up [17]. Moreover, heart failure incidence that 
was reported in the trastuzumab trials was not incorpo-
rated in the model since it is reversible, and is not associ-
ated with increased mortality [27, 28].
The model outputs were costs, life years (LYs), QALYs 
and ICERs. Costs, LYs, and QALYs were discounted at a 
yearly rate of 3% as recommended by the WHO [29].
Patient population
For each treatment strategy, a hypothetical cohort of 
10,000 patients was simulated.
Patients who enter the model are 45  years corre-
sponding with the median age of breast cancer patients 
in Africa [30]. Few studies were conducted concerning 
the clinicopathological and biological characteristics of 
breast cancer in sub-Saharan Africa [31]. Information 
on the incidence of HER2 positive, as presented in dif-
ferent studies, can be found in Table  1. Approximately 
25% of breast cancers are HER2 positive, and only those 
patients are eligible to receive trastuzumab. Therefore, 
the model was developed to evaluate the cost-effective-
ness of trastuzumab only in HER2 positive patients. In 
this study, we assumed all patients have HER2 positive 
early stage breast cancer which was completely resected. 
The background mortality information of the patients 
was retrieved from the WHO Global Health Observa-
tory data repository [32]. These values are different for 
patients from different countries (see Additional file  1: 
Table S1 and Additional file 2: Figure S1).
Remission
(R)
Death due to 
other causes (D)
Distant 
recurrence (DR) 
Local recurrence 
(LR)
Breast cancer 
death (BCD)
Fig. 1 Markov model structure
Table 1 HER2 positive incidence
Country Incidence Sources
Congo Not found
Ethiopia 23% [31]
Guinea Not found
Kenya 26% [33]
Namibia Not found
Nigeria 26% [34]
Rwanda 26.3% [35]
Uganda 22% [36]
Zambia Not found
Zimbabwe Not found
South Africa 22.50% [37]
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Costs
The total costs for the trastuzumab treatment were based 
on a first dose of 8 mg/kg, followed by sixteen doses of 
6 mg/kg for women that weigh 60 kg, based on the aver-
age weight of women in the selected countries [38, 39], 
considering 10% drug wastage. The price of trastuzumab 
treatment was estimated from extensive negotiations 
made as has been indicated as a realistic discount based 
on prior negotiations [40]. Since chemotherapy was used 
in both arms, we decided to disregard its price as it will 
add up the same amount in both arms costs and it will 
eventually cancel each other out in the ICER calculation. 
The prices for the local and distant recurrence states (LR 
and DR) were estimated from the prices in Bolivia, as 
previously published [17], normalized by GDP per cap-
ita. We assumed that there is no cost for the “Remission” 
state in African countries (see Table 2).
GDP per capita values were retrieved from the World 
Bank database [41].
Quality of life
We incorporated quality of life data from previously pub-
lished data and these are presented in Table 3 [17].
Sensitivity analyses
In order to assess the robustness of the model, a probabil-
istic sensitivity analysis was performed in order to assess 
the impact of uncertain variables on the results. Each 
variable was varied separately according to the probabil-
ity distribution of each variable as described in Table 3.
Results
In the base case analysis, trastuzumab yielded a gain 
ranging from 0.92 LYs in Nigeria to 1.07 LYs in South 
Africa, and 0.9 QALYs in Nigeria to 1.02 QALYs in South 
Africa. The ICER ranged from 19,534 USD/QALY in 
South Africa to 21,697 USD/QALY in Nigeria. Results are 
presented in Table 4 and in Additional file 3: Figure S2.
Uncertain values of the model were varied in a one-
way probabilistic sensitivity analysis. Results for all 
countries are presented in Fig. 2. The diagram presents 
ICER results from the 0.25 percentile to the 0.75 per-
centile. The probabilistic sensitivity analysis results 
were consistent through all 11 countries. The most 
sensitive variables were the discount rate, trastuzumab 
cost, and the hazard ratio. Furthermore, as can be 
seen in the figure, trastuzumab is not considered cost-
effective even with the low ICER values in the sensitiv-
ity analysis. Even though the prices used through most 
countries are identical as well as the drug efficacy, the 
ICER of each country is different due to the variation in 
background mortality of each country.
The individual estimates of valued based prices 
for trastuzumab are presented in Figs.  3, 4 and in 
Table 5. Since it was concluded that trastuzumab is not 
Table 2 Cost inputs
Country/costs (USD) Trastuzumab 
treatment
Local recurrence Distance 
recurrence
Congo 20,000 974 1356
Ethiopia 20,000 1323 1841
Guinea 20,000 1136 1581
Kenya 20,000 2769 3853
Namibia 20,000 9719 13,524
Nigeria 20,000 5446 7578
Rwanda 20,000 1456 2027
Uganda 20,000 1424 1981
Zambia 20,000 2695 3751
Zimbabwe 20,000 2090 2909
South Africa 20,000 11,836 16,470
Table 3 Model parameters used in the base case analysis and distributions used for the sensitivity analysis
Description Value Distribution Sources
Utilities
 Remission (R) 0.94 Beta (89, 6) [42, 43]
 Local recurrence (LR) 0.82 Beta (77, 23) [16]
 Distant recurrence (DR) 0.58 Beta (171, 79) [16]
Transition probabilities
 R > LR 0.029 Beta (27, 983) [26]
 R > DR 0.087 Beta (102, 1061) [15, 16]
 LR > R 0.1 Beta (111, 899) [16]
 LR > DR 0.261 Beta (119, 931) [16]
 DR > BCD 0.325 Beta (15, 20) [16]
 R, DR, LR > D All-cause mortality Age-specific mortality [32]
 Hazard ratio years 1–5 0.59 Log-Normal (− 0.527, 0.089) [16, 44]
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cost-effective in the examined countries, we calculated 
the VBP in such a way that would make the treatment 
considered as cost-effective in each country, when the 
WTP threshold is one GDP per capita. In order for the 
treatment to be considered as cost-effective in Afri-
can countries, significant price reductions would be 
required.  
Discussion
In this paper, the cost-effectiveness of trastuzumab for 
treating breast cancer was examined. Trastuzumab was 
compared to conventional chemotherapy treatment. In 
this analysis, trastuzumab treatment yields a gain ranging 
from 0.92 LYs in Nigeria to 1.07 LYs in South Africa, and 
0.9 QALYs in Nigeria to 1.02 QALYs in South Africa, with 
an incremental cost ranging from 19,561 USD in Nigeria 
to 19,997 USD in Congo, and an incremental cost-effec-
tiveness ratio ranging from 19,534 USD/QALY in South 
Africa to 21,697 USD/QALY in Nigeria per gained QALY.
The ICER results were comparable to previously pub-
lished results [19, 43–45]. Prior analyses in the UK, 
Australia, United States and Italy yielded similar results 
to those in our analysis. Other papers presented higher 
ICERs, which may be due to calculated costs and survival 
rates in Africa being significantly lower [18, 46, 47].
Table 4 Mean base case results
The standard error for LYs, QALYs, trastuzumab cost and no trastuzumab cost ranged from 0.052 LYs to 0.056 LYs, 0.049 QALYs to 0.053 QALYs, 27 USD to 328 USD, and 
27 USD to 324 USD respectively
Country Results LYs QALYs Costs (USD) ICER ($/QALY) ICER ($/LY)
Congo No Tzb arm 8.88 7.72 2588 20,520 19,701
Tzb arm 9.89 8.69 22,585
Diffrence 1.01 0.97 19,997
Ethiopia No Tzb arm 8.87 7.71 3541 19,990 19,384
Tzb arm 9.90 8.70 23,457
Diffrence 1.03 1.00 19,916
Guinea No Tzb arm 8.65 7.52 2955 20,692 20,025
Tzb arm 9.65 8.48 22,898
Diffrence 1.00 0.96 19,943
Kenya No Tzb arm 8.96 7.79 7467 19,601 18,709
Tzb arm 10.03 8.80 27,448
Diffrence 1.07 1.02 19,982
Namibia No Tzb arm 8.69 7.54 25,549 19,818 19,125
Tzb arm 9.72 8.53 45,173
Diffrence 1.03 0.99 19,624
Nigeria No Tzb arm 8.51 7.39 14,066 21,697 21,321
Tzb arm 9.43 8.29 33,628
Diffrence 0.92 0.90 19,561
Rwanda No Tzb arm 8.98 7.80 3919 19,751 19,004
Tzb arm 10.03 8.81 23,894
Diffrence 1.05 1.01 19,975
Uganda No Tzb arm 8.79 7.63 3793 20,477 19,806
Tzb arm 9.80 8.61 23,738
Diffrence 1.01 0.97 19,945
Zambia No Tzb arm 8.75 7.60 7116 20,330 19,473
Tzb arm 9.77 8.58 27,074
Diffrence 1.02 0.98 19,958
Zimbabwe No Tzb arm 8.57 7.44 5458 20,537 20,086
Tzb arm 9.56 8.41 25,303
Diffrence 0.99 0.97 19,845
South Africa No Tzb arm 8.76 7.61 31,160 19,534 18,719
Tzb arm 9.83 8.63 51,119
Diffrence 1.07 1.02 19,960
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Although the ICER results are quite similar to other 
studies, their meaning is different when examined in 
Africa. While trastuzumab can be considered as cost-
effective in HICs [5, 21, 42–44, 48], this is not the case 
in LMICs. ICER results in HICs were close or below 
the suggested threshold by WHO, one GDP per capita, 
as can be seen in Table 6, while the calculated ICERs in 
Africa were significantly higher than one GDP per capita 
for each examined country.
This study has several limitations. Since no clinical tri-
als were performed in Africa, there was a lack of informa-
tion regarding the efficacy of the drug in the population 
in this area. Therefore, for this analysis it was assumed 
that the findings from the performed clinical trials are 
relevant in Africa as well. Additionally, although the 
median age of patients in the HERA trial was 49, we used 
a different age (45) in our model under the assumption 
that the reported hazard ratio and the transition prob-
abilities depend on disease progression rather than the 
age. Furthermore, as indicated by previous literature 
[30], 45  years old is more representative of the general 
population of patients in sub-Saharan Africa. Another 
limitation concerns the omission of heart failure from 
the model. Although heart failure is reversible and is 
not associated with increased mortality it may have a 
mild effect on quality of life estimates. However, since 
Fig. 2 Sensitivity analysis results
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the incidence is very low [27, 28], we excluded it as it 
would have only a very minor impact on the results of 
the model. Moreover, given that the gap between the cur-
rent results and the cost-effectiveness threshold is very 
large, it can be assumed that the inclusion of heart fail-
ure will not change the results significantly. Moreover, 
as stated before, the transition probabilities were based 
on the HERA trial, which was conducted in HICs. These 
Fig. 3 Estimated treatment price in all examined countries compatible with value-based price (1 GDP per capita)
Fig. 4 Estimated treatment price in all examined countries compatible with value-based price (3 GDP per capita)
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probabilities were used due to lack of trials performed 
in sub-Saharan Africa. Therefore, it can be assumed that 
in reality these probabilities would be a bit different due 
to differences between health care systems in HICs and 
sub-Saharan Africa. Furthermore, not all the countries in 
Africa provide trastuzumab due to its high price. There 
is a significant lack of price transparency globally. Hence, 
the prices for all examined countries were merely esti-
mated. Lastly, since we concluded trastuzumab is not 
cost-effective in the current setting (12  months treat-
ment), further research concerning a recently suggested 
treatment duration (6/9 months treatment/9 weeks) [24, 
49] needs to be further investigated and maybe adopted 
in sub-Saharan Africa.
Africa is facing a major public health challenge from non-
communicable diseases. Even though infectious diseases 
are still a major concern in Africa, the overall disease bur-
den proportion in Africa associated with cancer is rising. It 
was predicted that by 2030, this region will experience an 
increase of more than 85% cancer burden [50]. One way to 
improve the current state in Africa is to make cancer drugs 
more accessible and affordable. Major improvements in the 
health system and cancer awareness are also crucial.
Conclusions
In this work we calculate the expected ICER gained by 
using trastuzumab in sub-Sahara Africa, and compare it 
to the threshold recommended by the WHO. Although 
the ICER results are quite similar to other studies, their 
meaning is different when examined in sub-Sahara 
Africa. While a trastuzumab can be considered as cost-
effective in HICs, this is not the case in LMICs. ICER 
results in HICs were close or below the suggested thresh-
old by WHO, one GDP per capita, while the calculated 
ICERs in Africa were significantly higher than one GDP 
per capita for each examined country.
Despite several limitations of our study, it seems that a 
significant reduction in trastuzumab’s price (compared to 
its price in HICs) would be required in order for it to be 
cost-effective in sub-Sahara Africa.
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Table 5 Value based price for each country
Country Value based price (1 GDP 
per capita)
Value based price 
(3 GDP per capita)
Congo 466 1392
Ethiopia 727 2012
Guinea 591 1659
Kenya 1395 4147
Namibia 5068 14,451
Nigeria 2832 7620
Rwanda 743 2179
Uganda 731 2083
Zambia 1332 3912
Zimbabwe 1139 3109
South Africa 5936 17,728
Table 6 ICER results and  their corresponding GDP 
per capita
Country ICER GDP 
per capita 
(USD)
Switzerland 40,505 EUR (45,950 USD) per LYG 57,579
United Kingdom 25,803 GBP (33,073 USD) per QALY 44,252
Sweden 41,500 USD per QALY 46,256
Norway 35,974 EUR (40,810 USD) per LYG 85,170
United States 26,417 USD per QALY 48,061
United States 39,892 USD per QALY 55,443
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